Letrozole with or without Paclitaxel and Carboplatin in Treating Patients with Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Inclusion Criteria
- Patients must have the psychological ability and general health that permits completion of the study requirements and required follow up
- All women will, by definition, be considered menopausal due to surgical removal of both ovaries prior to trial enrollment
- Patients must have newly diagnosed, stage II-IV low-grade serous ovarian cancer (submission of pathology report[s] required). Ovarian cancer = ovarian, fallopian tube and primary peritoneal cancers. p53 immunohistochemistry (IHC) is required and must show nonaberrant pattern (nonaberrant p53 expression is consistent with normal/wildtype TP53). If aberrant p53 expression is found on p53 IHC, the patient is NOT eligible (aberrant p53 expression is consistent with mutant TP53 and supports diagnosis of high grade serous ovarian cancer). A copy of the pathology report that includes the diagnosis of low grade serous ovarian cancer and nonaberrant p53 IHC result must be submitted in RAVE
- Appropriate stage for study entry based on the following diagnostic workup: * History/physical examination within 14 days prior to registration * Contrast-enhanced imaging of the chest, abdomen and pelvis within 28 days prior to registration
- Patients must have undergone an attempt at maximal upfront cytoreductive surgery, with either optimal (=< 1 cm diameter residual disease/nodule) or suboptimal residual disease (> 1 cm diameter residual disease/nodule) status allowed
- Patients must have undergone a bilateral salpingo-oophorectomy
- Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2 within 14 days prior to registration
- Patients must be within =< 8 weeks of primary cytoreductive surgery at time of randomization
- Patients must be able to take per oral (P.O.) medications
- Absolute neutrophil count (ANC) greater than or equal to 1,500/mcl (within 14 days prior to registration)
- Platelets greater than or equal to 100,000 cells/mcl (within 14 days prior to registration)
- Creatinine less than or equal to 1.5 x upper limit of normal (ULN) (within 14 days prior to registration)
- Bilirubin less than or equal to 1.5 x ULN (within 14 days prior to registration)
- Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) less than or equal to 3 x ULN (within 14 days prior to registration)
- The patient or a legally authorized representative must provide study-specific informed consent prior to study entry and, for patients treated in the United States (U.S.), authorization permitting release of personal health information
Exclusion Criteria
- Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial
- Patients may not have received neoadjuvant chemotherapy or radiotherapy for the treatment of this disease
- Patients may not have received previous hormonal therapy for the treatment of this disease
- Patients with known hypersensitivity to letrozole or hypersensitivity/intolerance to carboplatin/paclitaxel therapy
- Patients with severe cardiac disease: * Myocardial infarction or unstable angina within 6 months prior to registration * New York Heart Association (NYHA) class II or greater congestive heart failure
- Patients with known central nervous system metastases
- Patients with active (except for uncomplicated urinary tract infection) or uncontrolled systemic infection
- Patients with >= grade 2 baseline neuropathy
- Known human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial
Alaska
Anchorage
Arizona
Phoenix
Tucson
Arkansas
Ft. Smith
Hot Springs
Jonesboro
Little Rock
California
Antioch
Arroyo Grande
Burbank
Clovis
Dublin
Fremont
Fresno
Loma Linda
Modesto
Oakland
Rancho Cordova
Redwood City
Richmond
Rohnert Park
Roseville
Sacramento
San Francisco
San Jose
San Leandro
San Luis Obispo
San Rafael
Santa Clara
Santa Maria
Santa Rosa
South San Francisco
Stockton
Vacaville
Vallejo
Walnut Creek
Colorado
Aurora
Colorado Springs
Denver
Durango
Lakewood
Littleton
Longmont
Parker
Pueblo
Connecticut
Derby
Fairfield
Greenwich
Guilford
Hartford
New Haven
North Haven
Orange
Torrington
Trumbull
Waterbury
Waterford
Delaware
Frankford
Lewes
Newark
Rehoboth Beach
Seaford
Wilmington
District of Columbia
Washington
Florida
Fort Lauderdale
Fort Myers
Georgia
Augusta
Savannah
Hawaii
Aiea
Honolulu
Lihue
Idaho
Boise
Caldwell
Coeur D'Alene
Emmett
Fruitland
Meridian
Nampa
Post Falls
Sandpoint
Twin Falls
Illinois
Aurora
Bloomington
Canton
Carbondale
Carterville
Carthage
Centralia
Chicago
Danville
Decatur
Dixon
Effingham
Eureka
Evanston
Galesburg
Geneva
Glenview
Highland Park
Hinsdale
Kewanee
Lake Forest
Macomb
Mattoon
Mount Vernon
New Lenox
O'Fallon
Orland Park
Ottawa
Pekin
Peoria
Peru
Princeton
Springfield
Swansea
Urbana
Warrenville
Yorkville
Indiana
Carmel
Fort Wayne
Indianapolis
Richmond
South Bend
Iowa
Ames
Boone
Clive
Council Bluffs
Creston
Des Moines
Fort Dodge
Iowa City
Jefferson
Marshalltown
West Des Moines
Kansas
Coffeyville
Hays
Kansas City
Lawrence
Olathe
Overland Park
Pittsburg
Salina
Topeka
Westwood
Kentucky
Bardstown
Corbin
Lexington
London
Louisville
Madisonville
Paducah
Shepherdsville
Louisiana
New Orleans
Maine
Augusta
Bangor
Belfast
Biddeford
Brewer
Rockport
Sanford
Scarborough
Maryland
Baltimore
Massachusetts
Springfield
Worcester
Michigan
Ann Arbor
Battle Creek
Brighton
Canton
Caro
Chelsea
Clarkston
Detroit
East China
Farmington Hills
Flint
Grand Rapids
Grosse Pointe Woods
Kalamazoo
Lansing
Livonia
Macomb Township
Marlette
Muskegon
Niles
Norton Shores
Pontiac
Reed City
Rochester Hills
Saginaw
Saint Joseph
Sterling Heights
Tawas City
Traverse City
Warren
West Branch
Wyoming
Ypsilanti
Minnesota
Albert Lea
Bemidji
Burnsville
Cambridge
Coon Rapids
Edina
Fridley
Maple Grove
Maplewood
Minneapolis
Monticello
New Ulm
Princeton
Robbinsdale
Rochester
Saint Louis Park
Saint Paul
Shakopee
Stillwater
Waconia
Willmar
Woodbury
Wyoming
Mississippi
Jackson
Missouri
Ballwin
Bonne Terre
Branson
Cape Girardeau
Farmington
Jefferson City
Joplin
Kansas City
Lee's Summit
North Kansas City
Rolla
Saint Joseph
Saint Louis
Sainte Genevieve
Springfield
Sullivan
Sunset Hills
Washington
Montana
Anaconda
Billings
Bozeman
Great Falls
Kalispell
Missoula
Nebraska
Grand Island
Kearney
Lincoln
Omaha
Papillion
Nevada
Las Vegas
New Jersey
Basking Ridge
Middletown
Montvale
New Mexico
Albuquerque
New York
Albany
Brooklyn
Buffalo
Commack
New York
Rochester
Stony Brook
Syracuse
Uniondale
West Harrison
North Carolina
Chapel Hill
Charlotte
Clinton
Durham
Goldsboro
Hendersonville
Jacksonville
Winston-Salem
North Dakota
Bismarck
Fargo
Ohio
Beavercreek
Belpre
Boardman
Centerville
Chillicothe
Cincinnati
Cleveland
Columbus
Dayton
Delaware
Dublin
Findlay
Franklin
Gahanna
Greenville
Grove City
Kettering
Lancaster
Mansfield
Marietta
Marion
Mayfield Heights
Mount Vernon
Newark
Portsmouth
Springfield
Sylvania
Toledo
Troy
Warren
Westerville
Youngstown
Zanesville
Oklahoma
Oklahoma City
Tulsa
Oregon
Baker City
Bend
Clackamas
Coos Bay
Newberg
Ontario
Portland
Redmond
Tualatin
Pennsylvania
Allentown
Bethel Park
Bethlehem
Bryn Mawr
Chadds Ford
Collegeville
Danville
East Stroudsburg
Exton
Greensburg
Hazleton
Jefferson Hills
Lewisburg
Lewistown
Media
Monroeville
Paoli
Philadelphia
Pittsburgh
Pottsville
Scranton
Selinsgrove
State College
Uniontown
Washington
West Chester
Wexford
Wilkes-Barre
Wynnewood
Rhode Island
Providence
South Carolina
Bluffton
Charleston
South Dakota
Sioux Falls
Tennessee
Bristol
Kingsport
Memphis
Texas
Bryan
Houston
Utah
Farmington
Salt Lake City
South Jordan
Virginia
Bristol
Norton
Washington
Aberdeen
Bellingham
Bremerton
Burien
Centralia
Edmonds
Enumclaw
Everett
Federal Way
Issaquah
Kennewick
Lacey
Lakewood
Longview
Poulsbo
Seattle
Sedro-Woolley
Shelton
Tacoma
Vancouver
Walla Walla
Yelm
West Virginia
Charleston
Wisconsin
Burlington
Eau Claire
Fond Du Lac
Germantown
Grafton
Green Bay
Kenosha
La Crosse
Madison
Marinette
Marshfield
Milwaukee
Minocqua
Mukwonago
New Richmond
Oconomowoc
Oshkosh
Racine
Rice Lake
Sheboygan
Stevens Point
Summit
Two Rivers
Waukesha
Wauwatosa
West Allis
Weston
Wyoming
Cody
Sheridan
Ontario
Toronto
Korea, Republic of
Incheon
Seongnam City
Seoul
PRIMARY OBJECTIVE:
I. To examine if letrozole monotherapy/maintenance (L/L) is non-inferior to intravenous (IV) paclitaxel/carboplatin and maintenance letrozole (CT/L) with respect to progression-free survival (PFS) in women with stage II-IV primary low-grade serous carcinoma of the ovary or peritoneum after primary surgical cytoreduction.
SECONDARY OBJECTIVES:
I. To compare the nature, frequency and maximum degree of toxicity as assessed by Common Terminology Criteria for Adverse Events (CTCAE) version (v) 5.0 for each treatment arm.
II. To compare the relative frequency of objective tumor response in those with measurable disease after cytoreductive surgery for each treatment arm.
III. To compare overall survival for each treatment arm.
IV. To compare the CT/L and L/L arms with respect to patients’ adherence to letrozole therapy as measured by pill counts.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM I: Patients receive paclitaxel IV over 3 hours and carboplatin IV on day 1. Cycles repeat every 21 days for up to 6 cycles. Patients then receive letrozole orally (PO) once daily (QD) in the absence of disease progression or unacceptable toxicity.
ARM II: Patients receive letrozole PO QD in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up every 3 months for 2 years, every 6 months for 3 years, then annually thereafter.
Trial Phase Phase III
Trial Type Treatment
Lead Organization
NRG Oncology
Principal Investigator
Amanda Nickles Fader
- Primary ID NRG-GY019
- Secondary IDs NCI-2019-01460
- Clinicaltrials.gov ID NCT04095364